These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

44 related items for PubMed ID: 2975629

  • 21. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
    Milewicz T, Kostecka A, Rogatko I, Sztefko K, Kwiatkowska-Panek E, Radowick S, Krzysiek J.
    Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
    [Abstract] [Full Text] [Related]

  • 22. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
    Winkler UH, Sudik R.
    Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
    [Abstract] [Full Text] [Related]

  • 23. A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome.
    Nauck MA, Meier JJ, Wolfersdorff AV, Tillil H, Creutzfeldt W, Köbberling J.
    Acta Diabetol; 2003 Dec; 40(4):163-72. PubMed ID: 14740275
    [Abstract] [Full Text] [Related]

  • 24. Cyproterone acetate, an alternative progestogen in postmenopausal hormone replacement therapy? Effects on serum lipids and lipoproteins.
    Jensen J, Riis BJ, Christiansen C.
    Br J Obstet Gynaecol; 1987 Feb; 94(2):136-41. PubMed ID: 3030392
    [Abstract] [Full Text] [Related]

  • 25. 17 beta-Estradiol: oral or parenteral administration in hyperandrogenic women? Metabolic tolerance in association with cyproterone acetate.
    Vexiau P, Fiet J, Conard J, Abramovici Y, Boudou P, Hardy N, Consoli S, Cathelineau G.
    Fertil Steril; 1995 Mar; 63(3):508-15. PubMed ID: 7851579
    [Abstract] [Full Text] [Related]

  • 26. [Adrenal reactivity to prolonged-action ACTH in hirsute women treated with 50 mg of cyproterone acetate combined with percutaneous estradiol].
    Bercovici JP, Nahoul K, Tater D, Scholler R.
    Ann Endocrinol (Paris); 1986 Mar; 47(2):115-8. PubMed ID: 3026229
    [Abstract] [Full Text] [Related]

  • 27. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness.
    Gava G, Cerpolini S, Martelli V, Battista G, Seracchioli R, Meriggiola MC.
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):239-46. PubMed ID: 26932202
    [Abstract] [Full Text] [Related]

  • 28. Liver structure and function during long-term treatment with cyproterone acetate.
    Kaiser E, Gruner HS.
    Arch Gynecol; 1987 Aug; 240(4):217-23. PubMed ID: 2955749
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 micrograms) in 31 patients.
    Vexiau P, Vexiau-Robert D, Martineau I, Hardy N, Villette JM, Fiet J, Cathelineau G.
    Horm Metab Res; 1990 Apr; 22(4):241-5. PubMed ID: 2141001
    [Abstract] [Full Text] [Related]

  • 33. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
    Lepot MR, Gaspard UJ.
    Int J Fertil; 1987 Apr; 32 Suppl():15-20. PubMed ID: 2906343
    [Abstract] [Full Text] [Related]

  • 34. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
    Lemay A, Dodin S, Turcot L, Déchêne F, Forest JC.
    Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
    [Abstract] [Full Text] [Related]

  • 35. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A.
    Int J Fertil Menopausal Stud; 1995 Jan; 40 Suppl 2():98-104. PubMed ID: 8574257
    [Abstract] [Full Text] [Related]

  • 36. Metabolic effects of combined cyproterone acetate and percutaneous 17 beta oestradiol after six and twelve months therapy in 61 patients.
    Vexiau P, Gueux B, Vexiau-Robert D, Fiet J, Laureaux C, Tabuteau F, Brerault JL, Mathieson J, Cathelineau G.
    Horm Metab Res; 1988 Dec; 20(12):765-9. PubMed ID: 2975629
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
    Lepot MR, Gaspard UJ.
    Int J Fertil; 1987 Dec; 32 Suppl():15-20. PubMed ID: 2906343
    [Abstract] [Full Text] [Related]

  • 39. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
    Lemay A, Dodin S, Turcot L, Déchêne F, Forest JC.
    Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.